Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019.
Previously Cox was the CEO of Bioverativ (NASDAQ: [[ticker:BIIV]]), which he spun out from Biogen (NASDAQ: [[ticker:BIIB]]) in 2016 and oversaw through its 2018 acquisition by Sanofi (NASDAQ: [[ticker:SNY]]).
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
